52w high/low | ₹692 / ₹196 |
P/E ratio | 69.68 |
Dividend | 0.2 |
ROE | 23.59 |
ROCE | 31.3 |
Face value | 1 |
Book value | ₹20.51Cr |
Market capital | ₹3,674.85Cr |
What is shareholding pattern? Who are shareholders?
What is a cash flow statement?
What is a balance sheet?
What is a profit and loss statement?
What are dividends?
What are bonuses?
Promoted by Kantilal Shah and the Gujarat Industrial Investment Corporation, Gujarat Themis Biosyn (GTBL) was incorporated in Dec. '81 as a public limited company. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990. However, problems relating to purity levels, yield and imports put the company in the red and it became a BIFR case in 1990. Subsequently, it was taken over by a group consisting of Lyka Labs, Themis Chemicals, Kopran and Cadila. Also, Yuhan Corporation, South Korea, brought in technology and finance for running GTBL. During 1995-96 the paid-up share capital increased from Rs 11. 25 crores to Rs 11.